Site Selection Report for Life Sciences Companies in Europe 2018 is now available in Mandarin and can be downloaded free by clicking at the link below: 生命科学企业在欧洲的选址（2018年版 The report, compiled by KPMG in association with Venture Valuation, explores the when, where and how of successful European expansion. The publication looks beyond site selection to include … Continue reading The Mandarin translation of Site Selection Report for Life Sciences Companies in Europe 2018
Zurich / Montréal, November 26, 2018 As part of the ongoing commitment of Montréal InVivo to promote the economic development and growth of the life sciences and health technologies (LSHT) sector in Québec, Biotechgate, a company owned by Venture Valuation, and Montréal InVivo, the LSHT industrial cluster of the Montreal metropolitan area, announce a partnership … Continue reading Launch of a Directory of Life Sciences and Health Technologies companies with an exclusive database in Québec
RESI Conference, Boston, Sep 2018, 36 pages Deal and Product Valuations Deal and Product Valuations
Continuing a trend that began in 2017, this year has seen the rise of big investment deals in the biotech sector. Smaller biotechs are also cashing in as Big Pharma look to fill dwindling pipelines; according to Bloomberg data, biotech acquisitions are expected to be at the highest level for 12 years. Analysing this data from … Continue reading Whitepaper: The Rise of Bigger, Earlier M&A Deals for Biotech
The new Site Selection Report for Life Sciences Companies in Europe, compiled by KPMG in association with Venture Valuation, explores the when, where and how of successful European expansion. The publication looks beyond site selection to include key work streams involved in successfully commercializing pharmaceutical products in Europe. In the 2018 edition, we identify five … Continue reading Site Selection Report for Life Sciences Companies in Europe 2018
Biotech Investment Showcase, London, May 2018, 22 pages How to value a Biotech Start-up company
Current transfusion medicine entirely relies on donated blood. Megakaryon will change the transfusion practices by supplying safe and cost-saving platelets produced in vitro. Mass production in Japan is expected to begin in 2020. Venture Valuation (VV) interviewed Genjiro Miwa, CEO and Founder. Read the interview
